ENPP2 and neuroendocrine carcinoma: Plasma panels with specific miRNAs improve diagnosis (191, 192). CA19-9 gains accuracy combined with protein/inflammatory markers or ctDNA (174, 193, 194). sTRA predicts chemoresistance with CA19-9 (195). Autotaxin linked to therapy resistance (196). NETest aids early detection and monitoring of neuroendocrine cancers (50, 197, 198)